Abstract
Cs-131 is a radioisotope with a half-life of 9.7 days that is being increasingly used for prostate brachytherapy (PB). Due to its shorter half-life than other radioisotopes, including I-125 and Pd-103, Cs-131 may be associated with a shorter duration of irritative urinary symptoms. The outcome data with this isotope is still maturing. We present the updated, intermediate-term outcome of patients treated with Cs-131 PB monotherapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
